Longitudinal study of the substantia nigra in Parkinson disease: A high-field 1H-MR spectroscopy imaging study

Movement Disorders

Volumn 30, Issue 10, 2015, Pages 1400-1404

  Seraji Bozorgzad, Navid ^a   Bao, Fen ^a   George, Edwin ^a   Krstevska, Shana ^b   Gorden, Veronica ^a   Chorostecki, Jessica ^a   Santiago, Carla ^a   Zak, Imad ^a   Caon, Christina ^a   Khan, Omar ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Biomarkers; Magnetic resonance spectroscopy imaging; N acetyl aspartate; Parkinson's disease; Substantia nigra

Indexed keywords

CREATINE; N ACETYLASPARTIC ACID; ASPARTIC ACID; BIOLOGICAL MARKER; N-ACETYLASPARTATE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; SUBSTANTIA NIGRA; ANALOGS AND DERIVATIVES; METABOLISM; MIDDLE AGED; PROCEDURES;

AGED; ASPARTIC ACID; BIOMARKERS; CREATINE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SUBSTANTIA NIGRA;

EID: 84941072991     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26323     Document Type: Article

References (22)

1. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136:2419-2431.
2. Sharma S, Moon CS, Khogali A, et al. Biomarkers in Parkinson's disease (recent update). Neurochem Int 2013;63:201-229.
3. Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn Reson Q 1994;10:191-247.
4. Kato T, Nishina M, Matsushita K, et al. Neuronal maturation and N-acetyl-L-aspartic acid development in human fetal and child brains. Brain Dev 1997;19:131-133.
5. Pouwels PJ, Frahm J. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed 1997;10:73-78.
6. Moffett JR, Ross B, Arun P, et al. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007;81:89-131.
7. Groger A, Chadzynski G, Godau J, et al. Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. Eur Radiol 2011;21:1962-1969.
8. Oz G, Terpstra M, Tkac I, et al. Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med 2006;55:296-301.
9. Emir UE, Tuite PJ, Oz G. Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. PLoS One 2012;7:e30918.
10. Groger A, Kolb R, Schafer R, et al. Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging. PLoS One 2014;9:e84081.
11. Nie K, Zhang Y, Huang B, et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment. Parkinsonism Rel Disord 2013;19:329-334.
12. O'Neill J, Schuff N, Marks WJ, Jr., et al. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 2002;17:917-927.
13. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
14. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
15. Edden RA, Pomper MG, Barker PB. In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla. Magn Reson Med 2007;57:977-982.
16. Tkac I, Gruetter R. Methodology of H NMR spectroscopy of the human brain at very high magnetic fields. Appl Magn Reson 2005;29:139-157.
17. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
18. van Vliet SA, Blezer EL, Jongsma MJ, et al. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy. Brain Res 2008;1189:219-228.
19. Kempster PA, Gibb WR, Stern GM, et al. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry 1989;52:72-76.
20. Wellard RM, Briellmann RS, Jennings C, et al. Physiologic variability of single-voxel proton MR spectroscopic measurements at 3T. AJNR Am J Neuroradiol 2005;26:585-590.
21. Choe BY, Park JW, Lee KS, et al. Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy. Invest Radiol 1998;33:450-455.
22. Soher BJ, van Zijl PC, Duyn JH, et al. Quantitative proton MR spectroscopic imaging of the human brain. Magn Reson Med 1996;35:356-363.